Alkermes
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.About ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL.
ALKS Key Statistics
ALKS News
Alkermes ( ) First Quarter 2024 Results Key Financial Results Revenue: US$350.4m (up 22% from 1Q 2023). Net income: US$38.9m (up from US$41.8m loss in 1Q 202...
Reports Q1 revenue $350.4M, consensus $360.26M. “The first quarter of 2024 marks our first full quarter as a profitable, pure-play neuroscience company. During...
Alkermes (ALKS) reported $350.37 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 21.8%. EPS of $0.44 for the same...
Analyst ratings
54%
of 13 ratingsMore ALKS News
Alkermes (ALKS) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.01...
Alkermes reiterates its financial expectations for 2024, as set forth in its press release dated Feb. 15, 2024. Published first on TheFly – the ultimate source...